2 Clinical Trials for Various Conditions
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label pimavanserin treatment.
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression